| Dear Friend: We are pleased to provide you with the second edition of the MMRC Update. This monthly briefing was created to keep you informed of the MMRC’s progress toward its ultimate goal of accelerating drug development and improving patient outcomes. We hope you find this newsletter informative and we welcome any feedback you may have. However, if you would like to unsubscribe from this list, please click the link at the bottom of this message. For more information, contact us at info@themmrc.org Thank you for your support of the MMRC. |
MMRC Receives $1.5 Million Grant to Support Tissue Bank, Data Bank
The MMRC is pleased to announce that it has been awarded $1.5 million from The Pioneer Fund, a private family foundation based in Denver, Colo. These critical funds will be used to support the ongoing development and implementation of the MMRC's state-of-the-art Tissue Bank and Data Bank. The MMRC extends its deepest gratitude for the receipt of this generous grant.
MMRC Initiates GLP-Quality Tissue Bank Efforts
On Sept. 9-10, the MMRC convened a Good Laboratory Practices (GLP) training program and interactive workshop at the Mayo Clinic in Scottsdale, Ariz., to support the establishment of the MMRC's unique GLP-quality Tissue Bank. Led by Biologics Consulting Group, the objectives of this training were to 1) communicate key GLP tenets for the uniform processing and accrual of bone marrow samples into the MMRC Tissue Bank 2) discuss how the MMRC's customized data collection system will support the implementation of GLPs among MMRC Member Institutions and within the MMRC Tissue and Data Banks.
MMRC Interim Board Transitions to Formal Board of Directors
Following MMRC bylaws, the MMRC Interim Board of Directors transitioned to a formal board structure in conjunction with the Consortium's launch. Those who served on the Interim Board-- Gerald McDougall, Stuart Rosow, William Wilson III, Kenneth Anderson*, and Kathy Giusti*--were inducted as Members of the MMRC Board of Directors. In addition, the MMRC is pleased to welcome two new Members to the Board: Robert Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation and pioneer of the Foundation's aggressive and entrepreneurial drug discovery program, and Richard Brewer, former CEO of Scios, Inc., with more than 30 years overseeing operations at some of the most notable firms in the biopharmaceutical and medical device industries.
* ex officio non-voting
